Nomura M, Rainusso N, Lee Y, Dawson B, Coarfa C, Han R, Larson J, Shuck R, Kurenbekova L, Yustein, JT. 2019. Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. Journal of the National Cancer Institute. 111(11):1216-1227. doi: 10.1093/jnci/djz026.

Tsang S, Patel T, Yustein JT. 2019. Long Non-Coding RNAs Regulation of Therapeutic Resistance. Cancer Drug Resistance. 2:550-567, 10.20517/cdr.2019.58.

Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein JT, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. 2019. Emerging Novel Agents for Patients with Advanced Ewing Sarcoma: A Report From The Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. Faculty of 1000., 8: F1000 Faculty Rev-493, doi: 10.12688/f1000research.18139.1.

Rainusso N, Cleveland H, Hernandez J, Quintanilla N, Hicks J, Vasudevan S, Marco R, Allen-Rhoades W, Wang L, and Yustein JT. 2018. Generation of Patient-Derived Tumor Xenografts from Percutaneous Tumor Biopsies in Children with Bone Sarcomas. Pediatric Blood Cancer. e27579. doi: 10.1002/pbc.27579.

Fuja D, Rainusso N, Shuck R, Kurenbekova L, Donehower L, Yustein JT. 2018. Transglutaminase-2 Promotes Metastatic and Stem-Like Phenotypes in Osteosarcoma. American Journal of Cancer Research. 8(9):1752-1763.

Shapiro M, Tang T, Dasgupta A, Kurenbekova L, Shuck R, Gaber M., and Yustein JT. 2018. In vitro and in vivo characterization of a preclinical radiation-adapted model for Ewing sarcoma. International Journal of Radiation Oncology, Biology, Physics. 101(1):118-127. doi: 10.1016/j.ijrobp.2018.01.095. 

Dasgupta A, Trucco M, Rainusso N, Bernardi R, Shuck R, Kurenbekova L, Loeb D, Yustein JT. 2017. Metabolic Modulation of Ewing Sarcoma Cells Inhibits Tumor Growth and Stem Cell Properties. Oncotarget. 8(44):77292-77308. doi: 10.18632/oncotarget.20467.  

Satterfield L, Shuck R, Kurenbekova L, Allen-Rhoades W, Edwards D, Huang S, Rajapakshe K, Coarfa C, Donehower L, Yustein JT.  2017. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma. International Journal of Cancer. 141(10):2062-2075. doi: 10.1002/ijc.30909.

Dasgupta A, Nomura M, Shuck R, Yustein JT. 2017. Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue. International Journal of Molecular Sciences. 18(1): 23.

Techavichit P, Gao Y, Kurenbekova L, Shuck R, Donehower L, and Yustein JT. 2016. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasive and metastatic potential. BMC Cancer. 16(1):869. doi: 10.1186/s12885-016-2909-6.

Yang X, Chaudhury A, Zhang M, Savoldo B, Metelitsa L, Rodgers J, Yustein JT, Neilson J, Dotti G. 2016. T effector-memory cells are adapted to hypoxia through HIF1α and glycolytic metabolism. Journal of Clinical Investigation. 126(7):2678-88. doi: 10.1172/JCI85834.

Rao P, Zhao S, Zhao Y, Yu A, Rainusso N, Trucco M, Allen-Rhoades W, Satterfield L, Fuja D, Borra V, Man T, Donehower L, Yustein JT. 2015. Co-Amplification of Myc/Pvt1 and Homozygous Deletion of Nlrp1 Locus are the Frequent Genetics Changes in Mouse Osteosarcoma. Genes, Chromosomes and Cancer. doi: 10.1002/gcc.22291.

Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks J, Donehower L,  and Yustein JT. 2015. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. British Journal of Cancer. 113(9):1289-97. doi: 10.1038/bjc.2015.305. 

Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D, Shuck R, Rainusso N, Trucco M, Barkauskas D, Jo E, Ahern C, Hilsenbeck S, Donehower L, Yustein JT. 2015. Cross-Species Identification of a Plasma MicroRNA Signature for Detection, Therapeutic Monitoring, and Prognosis in Osteosarcoma. Cancer Medicine. 4(7):977-88.

Zhao S,  Kurenbekova L, Gao Y, Roos A, Creighton C, Rao P, Hicks J, Man T, Lau C, Brown A, Jones S, Lazar A, Ingram D, Lev D, Donehower L, Yustein JT. 2015. NKD2, a Negative Regulator of Wnt Signaling, Suppresses Tumor Growth and Metastasis in Osteosarcoma. Oncogene. doi:10.1038/onc.2014.429